JP2023522325A5 - - Google Patents
Info
- Publication number
- JP2023522325A5 JP2023522325A5 JP2022562676A JP2022562676A JP2023522325A5 JP 2023522325 A5 JP2023522325 A5 JP 2023522325A5 JP 2022562676 A JP2022562676 A JP 2022562676A JP 2022562676 A JP2022562676 A JP 2022562676A JP 2023522325 A5 JP2023522325 A5 JP 2023522325A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- lenvatinib
- miv
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2050430-4 | 2020-04-15 | ||
| SE2050430 | 2020-04-15 | ||
| PCT/SE2021/050338 WO2021211039A1 (en) | 2020-04-15 | 2021-04-14 | Miv-818/lenvatinib combination therapy for liver cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522325A JP2023522325A (ja) | 2023-05-30 |
| JP2023522325A5 true JP2023522325A5 (https=) | 2024-03-22 |
| JP7709456B2 JP7709456B2 (ja) | 2025-07-16 |
Family
ID=78084457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562676A Active JP7709456B2 (ja) | 2020-04-15 | 2021-04-14 | 肝臓癌のためのｍｉｖ－８１８／レンバチニブ併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240024342A1 (https=) |
| EP (1) | EP4135849B1 (https=) |
| JP (1) | JP7709456B2 (https=) |
| KR (1) | KR20230003522A (https=) |
| CN (1) | CN115485029A (https=) |
| AU (1) | AU2021255043B9 (https=) |
| CA (1) | CA3174940A1 (https=) |
| ES (1) | ES3027841T3 (https=) |
| HR (1) | HRP20250669T1 (https=) |
| HU (1) | HUE071473T2 (https=) |
| PL (1) | PL4135849T3 (https=) |
| TW (1) | TW202200140A (https=) |
| WO (1) | WO2021211039A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113453685A (zh) * | 2019-02-18 | 2021-09-28 | 美迪维尔公司 | 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法 |
| TW202444368A (zh) * | 2023-03-30 | 2024-11-16 | 瑞典商米迪維艾克提伯拉公司 | 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ729118A (en) * | 2014-08-25 | 2022-02-25 | Medivir Ab | Dioxolane analogues of uridine for the treatment of cancer |
| CA3014769C (en) * | 2016-03-02 | 2024-01-09 | Medivir Aktiebolag | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
| RU2019134940A (ru) * | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
| CN113453685A (zh) * | 2019-02-18 | 2021-09-28 | 美迪维尔公司 | 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法 |
| US11098002B2 (en) * | 2019-07-26 | 2021-08-24 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease |
-
2021
- 2021-04-14 HU HUE21787576A patent/HUE071473T2/hu unknown
- 2021-04-14 JP JP2022562676A patent/JP7709456B2/ja active Active
- 2021-04-14 EP EP21787576.4A patent/EP4135849B1/en active Active
- 2021-04-14 TW TW110113451A patent/TW202200140A/zh unknown
- 2021-04-14 WO PCT/SE2021/050338 patent/WO2021211039A1/en not_active Ceased
- 2021-04-14 PL PL21787576.4T patent/PL4135849T3/pl unknown
- 2021-04-14 AU AU2021255043A patent/AU2021255043B9/en active Active
- 2021-04-14 CN CN202180028332.9A patent/CN115485029A/zh active Pending
- 2021-04-14 ES ES21787576T patent/ES3027841T3/es active Active
- 2021-04-14 HR HRP20250669TT patent/HRP20250669T1/hr unknown
- 2021-04-14 KR KR1020227039743A patent/KR20230003522A/ko active Pending
- 2021-04-14 CA CA3174940A patent/CA3174940A1/en active Pending
- 2021-04-14 US US17/919,221 patent/US20240024342A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022121594A5 (https=) | ||
| JP2015536964A5 (https=) | ||
| JP2016006096A5 (https=) | ||
| JP2018507197A5 (https=) | ||
| JP2019507764A5 (https=) | ||
| JP2017536344A5 (https=) | ||
| JP2019529518A5 (https=) | ||
| JP2018513150A5 (https=) | ||
| JP2014506913A5 (https=) | ||
| JP2019519498A5 (https=) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2017525730A5 (https=) | ||
| JP2020510054A5 (https=) | ||
| JP2009543802A5 (https=) | ||
| JP2014524469A5 (https=) | ||
| JP2014508804A5 (https=) | ||
| RU2011142750A (ru) | Способ лечения путем применения комбинированной терапии | |
| JP2014510729A5 (https=) | ||
| JP2023522325A5 (https=) | ||
| JP2016503414A5 (https=) | ||
| JP2016502981A5 (https=) | ||
| JP2019038796A5 (https=) | ||
| RU2018134336A (ru) | Комбинированная терапия сорафенибом или регорафенибом и фосфорамидатным пролекарством троксацитабина | |
| JP2017510660A5 (https=) | ||
| JP2012522841A5 (https=) |